Urinary mutagenicity and bladder cancer risk in northern New England
- PMID: 38465801
- PMCID: PMC11089907
- DOI: 10.1002/em.22588
Urinary mutagenicity and bladder cancer risk in northern New England
Abstract
The etiology of bladder cancer among never smokers without occupational or environmental exposure to established urothelial carcinogens remains unclear. Urinary mutagenicity is an integrative measure that reflects recent exposure to genotoxic agents. Here, we investigated its potential association with bladder cancer in rural northern New England. We analyzed 156 bladder cancer cases and 247 cancer-free controls from a large population-based case-control study conducted in Maine, New Hampshire, and Vermont. Overnight urine samples were deconjugated enzymatically and the extracted organics were assessed for mutagenicity using the plate-incorporation Ames assay with the Salmonella frameshift strain YG1041 + S9. Logistic regression was used to estimate the odds ratios (OR) and 95% confidence intervals (CI) of bladder cancer in relation to having mutagenic versus nonmutagenic urine, adjusted for age, sex, and state, and stratified by smoking status (never, former, and current). We found evidence for an association between having mutagenic urine and increased bladder cancer risk among never smokers (OR = 3.8, 95% CI: 1.3-11.2) but not among former or current smokers. Risk could not be estimated among current smokers because nearly all cases and controls had mutagenic urine. Urinary mutagenicity among never-smoking controls could not be explained by recent exposure to established occupational and environmental mutagenic bladder carcinogens evaluated in our study. Our findings suggest that among never smokers, urinary mutagenicity potentially reflects genotoxic exposure profiles relevant to bladder carcinogenesis. Future studies are needed to replicate our findings and identify compounds and their sources that influence bladder cancer risk.
Keywords: bladder; cancer; mutagenicity; smoking; urine.
© 2024 The Authors. Environmental and Molecular Mutagenesis published by Wiley Periodicals LLC on behalf of Environmental Mutagenesis and Genomics Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Conflict of interest statement
Declaration of Competing Interest
The authors declare no financial or personal conflicts of interest.
Similar articles
-
Mutagenic activity of overnight urine from healthy non-smoking subjects.Environ Mol Mutagen. 2007 Mar;48(2):143-50. doi: 10.1002/em.20277. Environ Mol Mutagen. 2007. PMID: 17295305
-
Urine pH and Risk of Bladder Cancer in Northern New England.Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1323-1327. doi: 10.1158/1055-9965.EPI-22-0801. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37351876 Free PMC article.
-
A case-control study of smoking and bladder cancer risk: emergent patterns over time.J Natl Cancer Inst. 2009 Nov 18;101(22):1553-61. doi: 10.1093/jnci/djp361. Epub 2009 Nov 16. J Natl Cancer Inst. 2009. PMID: 19917915 Free PMC article.
-
Genotoxic risk of passive smoking.Rev Environ Health. 1984;4(2):161-78. Rev Environ Health. 1984. PMID: 6397792 Review.
-
Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions.FASEB J. 2013 Jun;27(6):2090-100. doi: 10.1096/fj.12-227074. Epub 2013 Feb 28. FASEB J. 2013. PMID: 23449930 Review.
References
-
- Andre V, Lebailly P, Deslandes E, Henry-Amar M, Gauduchon P. 2002. Biomonitoring of urine mutagenicity with the Ames test: improvement of the extraction/concentration method. Mutat Res 520(1–2):199–205. - PubMed
-
- Baris D, Karagas MR, Koutros S, Colt JS, Johnson A, Schwenn M, Fischer AH, Figueroa JD, Berndt SI, Han S, Beane Freeman LE, Lubin JH, Cherala S, Cantor KP, Jacobs K, Chanock S, Chatterjee N, Rothman N, Silverman DT. 2013. Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England. Int J Cancer 132(1):162–173. - PMC - PubMed
-
- Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, Schwenn M, Colt JS, Cherala S, Samanic C, Waddell R, Cantor KP, Schned A, Rothman N, Lubin J, Fraumeni JF Jr., Hoover RN, Kelsey KT, Silverman DT. 2009. A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst 101(22):1553–1561. - PMC - PubMed
-
- Baris D, Waddell R, Beane Freeman LE, Schwenn M, Colt JS, Ayotte JD, Ward MH, Nuckols J, Schned A, Jackson B, Clerkin C, Rothman N, Moore LE, Taylor A, Robinson G, Hosain GM, Armenti KR, McCoy R, Samanic C, Hoover RN, Fraumeni JF Jr., Johnson A, Karagas MR, Silverman DT. 2016. Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic. J Natl Cancer Inst 108(9). - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical